Coherus Chief: FTC Must Probe Originators’ Anti-Competitive Tactics

Bundled rebate contracts for biologic brands that are designed to thwart biosimilar competition in the US are anti-competitive practices that deserve Federal Trade Commission action, biosimilar developer Coherus’ chief argues in a newspaper opinion piece.

FTC
The Federal Trade Commission must act on anti-competitive biologics rebate bundling that is stifling biosimilars uptake, Coherus chief Denny Lanfear insists • Source: Shutterstock

Biologics originators are using “a combination of coercive, anti-competitive tactics to box out biosimilars”, an approach that merits investigation by the Federal Trade Commission, Coherus BioSciences'’ president, CEO and chairman Denny Lanfear argues in an opinion piece published this week in the Wall Street Journal.

Arguing that branded biologics firms were being allowed to maintain their monopolies almost a decade after the 2010 Biologics Price...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products

Water Pressure: How European Industry Is Pushing Back On The UWWTD

 
• By 

Concern continues to build in the European generics industry over the threat posed by the EU’s Urban Wastewater Treatment Directive, which was one of the hottest topics of discussion at Medicines for Europe’s legal and annual conferences. And now, the association has intervened in a legal challenge.

Pertuzumab Leader Henlius Receives EU Accreditation For Production Lines

 
• By 

Shanghai Henlius Biotech has received EMA GMP certification for its HLX14 and HLX11 biosimilar production lines, paving the way for faster market entry in the EU and reinforcing its global manufacturing credentials.

Alvotech Boosts Packaging Abilities With Ivers-Lee Acquisition

 
• By 

Alvotech has acquired long-time partner Ivers-Lee to expand its in-house capacity for assembly and packaging ahead of key planned biosimilar launches in 2025, strengthening operational control and supporting global growth.